According to Wallstreetcn, Novo Nordisk CEO said an additional 4,000 departures brought the total number of layoffs related to business integration to 13,000, and that it is time to further push the company’s diversification. The company will create a new business segment called blood and endocrine diseases, and liver disease is also a clear expansion direction. Despite recent setbacks, cardiovascular disease remains another clear expansion direction.